Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic
Jason Coloma remembers when Maze Therapeutics was nothing more than a bunch of PowerPoint slides. Several months after revealing exactly what his team of scientists have been up to, the chief executive is now gunning for the clinic with another $190 million in tow — and he says an IPO isn’t entirely out of the question.
“I mean, the good thing is with the financial flexibility that we now have, we’ve done a nice job,” Coloma said when asked about a public debut. “We’ll look at different options, but I think that would even include even staying private or looking at different business development transactions that might be helpful for us to kind of think of different ways to advance our pipeline.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
